Is a statin drug right for you? Researchers try to right-size the risk

The correlation between math and life-or-death scenarios has never been more apparent than in the field of cardiovascular health. In November 2023, a groundbreaking model for predicting the risk of developing atherosclerotic cardiovascular disease was introduced, garnering accolades for its utilization of a larger, more diverse population sample of Americans. However, concerns arose that as many as 40% of U.S. adults might no longer qualify for statins, a common medication used to combat cholesterol build-up in arteries.

The crux of the issue lies in determining the threshold at which individuals should be prescribed statins based on their risk factors. The latest research suggests that adjusting the threshold based on the new risk calculator would result in a similar number of individuals qualifying for statin treatment as before. This decision holds significant weight as cardiovascular disease remains the leading cause of mortality, with atherosclerotic cardiovascular disease ranking highest in preventable deaths and illnesses in both men and women.

A recent research letter published in JAMA Cardiology sheds light on the potential impact of different threshold levels on statin eligibility. By considering a 3%, 4%, or 5% risk of a heart attack or stroke over a 10-year period, the study suggests that maintaining the threshold at 3% would align with the previous eligibility criteria. This lower threshold reflects the enhanced data provided by the new model, known as PREVENT, which accounts for a variety of metabolic conditions in addition to heart health.

While statins offer significant benefits in reducing cardiovascular risk, they are not without drawbacks. Some individuals may experience muscle pain, while a more concerning side effect is the increased risk of developing type 2 diabetes. Despite these considerations, the potential benefits of statins in preventing heart attacks and strokes may outweigh the risks for many individuals.

As the medical community awaits updated guidelines from organizations like the American Heart Association and the American College of Cardiology, the conversation around statin eligibility continues to evolve. Experts emphasize the importance of individualized care, taking into account each patient’s unique needs and preferences when considering statin therapy.

Ultimately, the goal is to ensure that the right individuals receive statin treatment based on their risk profile and potential benefits. By leveraging advanced risk assessment tools and engaging in open dialogues between healthcare providers and patients, the medical community aims to strike a balance between maximizing cardiovascular protection and minimizing potential risks associated with statin therapy.